We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Iron replacement in anthracycline-related cardiac dysfunction: fuel on the fire?
- Authors
Nazir, Muhummad Sohaib; Lyon, Alexander R; Southworth, Richard
- Abstract
The article discusses the potential benefits and risks of intravenous iron replacement therapy for patients with heart failure. Several large randomized controlled trials have shown that intravenous iron supplementation can improve functional capacity and reduce heart failure hospitalizations in these patients. However, there are important considerations for patients who develop anthracycline-induced left ventricular systolic dysfunction, as anthracyclines can increase cardiac iron uptake and exacerbate cardiotoxicity. The authors suggest that intravenous iron replacement should be considered after completion of anthracycline chemotherapy, clearance of anthracyclines from the heart, and recovery from any acute cardiac dysfunction. They also recommend careful monitoring and consideration of oral iron supplementation for individuals at higher risk.
- Subjects
HEART failure; MEDICAL sciences; LEFT ventricular dysfunction; MAJOR adverse cardiovascular events; BRAIN natriuretic factor; IRON supplements; ADRENERGIC beta blockers; ACE inhibitors
- Publication
European Heart Journal, 2024, Vol 45, Issue 34, p3132
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehae411